Thus, these findings mirror the trend observed in this study in animal models of pancreatic cancer, endotoxemia and sepsis, which implies that TREM-1 inhibitor specificity and timing of treatment initiation can strongly impact its therapeutic efficacy in cancer and inflammatory disease. The gene discussed is TREM1; the disease is familial pancreatic carcinoma.